Xeris Biopharma Holdings Inc

XERS

Add to Watchlist

6.240USD

-0.140-2.19%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Xeris Biopharma Holdings Inc's Score

Industry at a Glance

Industry Ranking

43 / 155

Overall Ranking

119 / 4482

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Xeris Biopharma Holdings Inc Highlights

StrengthsRisks

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on improving patient lives by developing and commercializing products across a range of therapies. It has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. It also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. It is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 78.05% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 81.01, at a high 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 619.66K shares of this stock.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

11.143

Target Price

+74.65%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Xeris Biopharma Holdings Inc is 8.95, ranking 20 out of 155 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 83.13M, representing a year-over-year increase of 38.27%, while its net profit experienced a year-over-year increase of 124.23%.

Score

Industry at a Glance

Previous score

8.95

Change

0



Financials

6.98

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.78

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Xeris Biopharma Holdings Inc is 7.59, ranking 59 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is 81.01, which is 2179.27% below the recent high of 1846.38 and 201.03% above the recent low of -81.84.

Score

Industry at a Glance

Previous score

7.59

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 43/155

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Xeris Biopharma Holdings Inc is 8.57, ranking 26 out of 155 in the Pharmaceuticals industry. The average price target is 10.00, with a high of 18.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

8.57

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Xeris Biopharma Holdings Inc is 7.25, ranking 46 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 6.89 and the support level at 5.71, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.43

Change

-0.18

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Xeris Biopharma Holdings Inc is 5.00, ranking 73 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 57.26%, representing a quarter-over-quarter decrease of 4.21%. The largest institutional shareholder is James Simons, holding a total of 619.66K shares, representing 0.36% of shares outstanding, with 73.42% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

10.97M

+5.58%

D. E. Shaw & Co., L.P.

7.57M

+29.71%

Geode Capital Management, L.L.C.

4.28M

+3.28%

State Street Investment Management (US)

4.12M

+10.13%

Qube Research & Technologies Ltd

3.50M

+6.82%

Driehaus Capital Management, LLC

2.98M

+13.80%

Nuveen LLC

2.72M

-0.72%

Two Sigma Investments, LP

2.58M

+2.96%

Morgan Stanley & Co. LLC

2.43M

-14.61%

Wellington Management Company, LLP

2.29M

+293.59%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Xeris Biopharma Holdings Inc is 4.75, ranking 83 out of 155 in the Pharmaceuticals industry. The company's beta value is 0.78. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Xeris Biopharma Holdings Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Xeris Biopharma Holdings Inc

XERS

7.52 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Catalyst Pharmaceuticals Inc

CPRX

9.11 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Jazz Pharmaceuticals PLC

JAZZ

8.81 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Kiniksa Pharmaceuticals International PLC

KNSA

8.59 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

8.52 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment